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Abstract
Background: There has been a considerable amount of debate among the research community whether cannabis
use may cause schizophrenia and whether cannabis use of patients with schizophrenia is associated with earlier
and more frequent relapses. Considering that studies exploring patients’ view on controversial topics have
contributed to our understanding of important clinical issues, it is surprising how little these views have been
explored to add to our understanding of the link between cannabis and psychosis. The present study was
designed to elucidate whether patients with schizophrenia who use cannabis believe that its use has caused their
schizophrenia and to explore these patients other beliefs and perceptions about the effects of the drug.
Methods: We recruited ten consecutive patients fulfilling criteria for paranoid schizophrenia and for a harmful use
of/dependence from cannabis (ICD-10 F20.0 + F12.1 or F12.2) from the in- and outpatient clinic of the Psychiatric
University Hospital Zurich. They were interviewed using qualitative methodology. Furthermore, information on
amount, frequency, and effects of use was obtained. A grounded theory approach to data analysis was taken to
evaluate findings.
Results: None of the patients described a causal link between the use of cannabis and their schizophrenia. Disease
models included upbringing under difficult circumstances (5) or use of substances other than cannabis (e. g.
hallucinogens, 3). Two patients gave other reasons. Four patients considered cannabis a therapeutic aid and
reported that positive effects (reduction of anxiety and tension) prevailed over its possible disadvantages
(exacerbation of positive symptoms).
Conclusions: Patients with schizophrenia did not establish a causal link between schizophrenia and the use of
cannabis. We suggest that clinicians consider our findings in their work with patients suffering from these
co-occurring disorders. Withholding treatment or excluding patients from certain treatment settings like day-care
facilities or in patient care because of their use of cannabis, may cause additional harm to this already heavily
burdened patient group.
Background
There still is a debate among the research community
whether cannabis use may cause schizophrenia [1,2] and
whether cannabis use of patients with schizophrenia
might lead to a more untoward outcome like earlier and
more frequent relapses [3].
Arguments in this debate primarily stem from cohort
studies [4], systematic reviews [5], and meta analyses
[6]. Considering that studies exploring patients’ view on
a controversial topic have contributed to our knowledge
of important clinical issues [7], such as patients’ reasons
for following or refusing medical recommendations
[8,9], and patients needs and wishes at the end of life
[10], it is surprising how little these views have been
explored to add to our understanding of the link
between cannabis and psychosis.
Even though patients’ beliefs on the role of cannabis
in the pathogenesis of schizophrenia have - to our
knowledge - not been studied so far, some studies have
explored reasons for cannabis and/or other substance
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use in psychosis, mainly by means of questionnaires (e.g.
the Reasons for Cannabis Use Questionnaire, the
Psychosis and Drug Abuse Scale (PADAS) and the Can-
nabis Use Effects Survey [11-13]).
Generally, it was found that the most frequent reasons
for cannabis use among individuals with psychotic disor-
ders were similar to those of healthy subjects (e. g. a
wish to relax, to be high, to reduce boredom, social
motives [e. g. “to go along with the group"], improving
sleep, anxiety, and agitation). However, some of these
studies also found that an important part of patients
(11-40%) reported to use cannabis to reduce hallucina-
tions [12,14,15].
These rather unexpected statements stand in contra-
diction to the widely held belief of most clinicians that
cannabis use is specifically unhealthy for patients with
schizophrenia and underline the importance of integrat-
ing patients’ views into treatment, since they may influ-
ence adherence to medical treatment and therefore have
an impact on the overall outcome [8,16].
The present exploratory study uses a grounded theory
approach, conducting narrative interviews [17] to
explore - to our knowledge for the first time - disease
models of patients with schizophrenia who use cannabis
and to clarify whether patients believe in a causal link
between cannabis use and schizophrenia.
Method
Ten consecutive patients fulfilling criteria for schizo-
phrenia (ICD-10 F20.0) and for a current harmful use
of/dependence from cannabis (ICD-10 F12.1 or F12.2)
were recruited from the in- and outpatient clinic of the
Psychiatric University Hospital Zurich. Further inclusion
criteria included being 18 years of age or older and will-
ingness to give written informed consent. Exclusion cri-
teria were insufficient language skills, acute psychosis or
intoxication and a diagnosis of personality disorder. For
each patient the full patient’s chart from the clinic with
a complete biographical and psychiatric history was
available, including diagnosis according to ICD-10.
In order to identify patients’ personal perceptions and
motivations we used single, unstructured, in depth inter-
views [18] lasting for about 1.5 hours. Our topic guide
(vide infra) provided a flexible interview framework. A
definitive version of it had emerged after the 4th narra-
tive. Interviews started with a narrative opening question
concerning patient’s subjective disease models. Probes
were used to explore the role of cannabis in case it was
not covered spontaneously in patients’ initial narrative.
In addition, we allowed themes and motives identified
in earlier interviews to be explored in those following,
combining the principles of maximum variation and
complexity reduction to simultaneously widen the scope
of results and examining previous assumptions [19].
Care was taken to shape a conversation in which the
patient felt free to present his or her own view [20].
All interviews were conducted by the same researcher in
the outpatient clinic. Patients received a compensation of
20 Swiss Francs for participation. In addition to the inter-
views, information on prescribed medication and exact
diagnosis (ICD-10) was obtained from clinical records.
A grounded theory approach to data analysis was
taken to evaluate findings. This meant allowing the data
to “speak for themselves” rather than approaching the
data within existing theoretical frameworks [21]. All
interviews were tape recorded and then transcribed in
full. Transcripts were compared with tapes by the
research team and validated with patients, if necessary.
Validation of transcripts with patients was necessary in
three cases. This was due to technical difficulty (e.g. dis-
tracting side noise on tape).
Materials were coded using an inductive qualitative
procedure [22]. Categories obtained were discussed in
the research team to validate ratings and achieve con-
sensus. AB applied the final code, with confirmation of
consistency through blind dual coding of two transcripts
with ML. Authorization by the local ethics committee
was obtained before the study was conducted. All
patients were assured complete confidentiality and pro-
vided their written informed consent to the study, speci-
fically to the tape-recorded interviews.
Topic Guide
« How would you describe the condition you are suffer-
ing from? »
« What is/are the cause/s of your illness? »
« You might have heard that there might be a rela-
tionship between the consumption of cannabis and the
likelihood of developing a mental disorder at a later
time. How do you feel about that? »
« What are the effects if you consume cannabis? »
« Do these effects vary over time or condition you are
in when smoking? »
Results
Patients’ characteristics, diagnosis and consumption pat-
terns are described in table 1.
Patients’ explanatory models about the origin of their
mental illness
Nine of the interviewed patients regarded themselves as
suffering from a mental disorder. While seven patients
identified themselves as suffering from schizophrenia,
one viewed himself as being depressed and one
described himself as emotionally unstable. One patient
did not regard himself as suffering from a mental disor-
der at all, but stated to only have some mental health
problems.
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In our sample all patients had developed thorough
explanatory models about the origin of their mental
condition. Although each individual etiological concept
was unique in its own way, it was possible to identify
common major themes and shared features. It has to be
noted, however, that some overlapping between themes
occurred. Three of the ten patients identified more than
one contributing cause and had adopted a multi-factor-
ial explanatory model.
We identified five major themes on perceived causa-
tion, which we characterize below, starting with the
most commonly expressed perception.
Family induced
Most frequently patients attributed the development of
their mental disorder to their upbringing under difficult
circumstances, comprising parental neglect, parental
overprotection, and physical or psychological abuse:
«... I suffer from paranoia. That is because I was bea-
ten at home and I was neglected. What is left over is
anxiety. It is still enough if someone raises the voice
to me. It will scare me. Both my parents, my father
and my mother, beat me physically...»
S.F. 36y. male, cannabis use since age 16
«...It all started when I was around 12 - 13 years old.
My parents were constantly quarrelling, so I began
daydreaming: Everything what happened was just a
theatrical play with me becoming merely a facade.
Because of that I had no chance to relax. The lack
of relaxation is the reason, why I suffer from schizo-
phrenia today...»
M.B. 40y. male, cannabis use since age 14
«...Discrimination. My mother completely denied me
when she got a new partner. I got my voices because
of the denial. The entire story with my psychosis
started because of discrimination...»
N.A. 44y. female, cannabis use since age 20
Drug induced
Repeatedly patients described an alteration of their men-
tal state, after a moderate or excessive use of one or
Table 1 Patients’ characteristics, cannabis use, and medication
subject age sex Initials use of cannabis prescribed drugs
at time of
interview**
diagnosis
(ICD-10)
occupation
starting
age
years of
consumption
max.
quanity in
joints/d
way of
consumption
frequency
of use
VP1 26 m P.O. 12 14 10 smoking 2-3/w none F20.0 F12.24
F20.0,
disability
pension
commercial
clerk,
VP2 27 m P.A. 16 11 7 smoking 2/w C, AD, B F11.22,
F12.25,
F14.26,
F13.20
disability
pension
medical school
VP3 42 m M.B. 14/15 27 12 smoking daily N F20.0 F.12.25 drop out
commercial
clerk,
VP4 27 m K.C. 12 15 20 smoking 2/w M, B, N F20.0,
F11.22,
F12.24
disability
pension
commercial
clerk,
VP5 36 m S.F. 16 20 3 smoking daily N, AD F20.0,
F12.25, F33.0
50% workload
lumberjack,
VP6 43 m H.G 20 23 15 smoking 1-2/w N, AD F11.22,
F12.24, F20.0
disability
pension high
school drop
VP7 34 m Z.A. 17 17 15 smoking sporadic N, MS, M F20.03,
F12.20
out, disability
pension
VP8 51 m R.S. 17 34 10 smoking sporadic N, MS, AD F20.0, F43.1,
F14.2, F12.24
mason,
disability
pension
VP9 44 f N.A. 20 24 5 smoking sporadic N F41.3,
F20.0,12.24
social worker,
100% workload
VP10 53 f B.L. 16 37 4 smoking sporadic N, B F20.01,
F11.22,
F12.2, F50.1
waitress, 100%
workload
**AD = antidepressants; N = neuroleptics; R = Ritalin®; C = Concerta®; B = benzodiazepines; M = modafinil; MS = mood stabilizers
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more legal or illegal substances. They thought that this
alteration had led to a permanent damage of their men-
tal health. Our patients attributed the capability of indu-
cing such changes solely to hallucinogens and non-
hallucinogenic amphetamines. Interestingly, cannabis
was rarely mentioned in this context.
«...To put it simply: Excessive labor of the brain,
because of to much methamphetamine. That was
difficult. I went to a friend of mine, banged against
her door and told her that she should be watching
out for me... It went on for an entire night, it just
was too much. I think the reason (for my illness) is
an overwork of my brain...»
K.C. 27y. male, cannabis use since age 12
«...I once took too much ecstasy. They took me to
the Klinik Hard (regional hospital in the Zurich
area) and after this event it was a gradual process
until I got schizophrenia...»
P.O. 26y. male, cannabis use since age 12
«...I had used other stuff before, LSD, so I had heard
voices at the age of 17-18 years. Also alcohol played
a major role in developing this illness...»
H.G. 43y. male, cannabis use since age 20
«...At a party I was finally offered a drug cocktail
containing stimulants and LSD and that is when my
illness really got rolling...»
Z.A. 34y. male, cannabis use since age 17
Socially induced
Some explanatory models given by patients focused on
social factors as the main reason for developing schizo-
phrenia. Factors like loneliness, conflicts in partnership,
and problems at work or school were mentioned, but
were not seen as causally related. The main motive
identified was “social pressure” as exemplified below:
«...My family put a lot of social pressure on me and I
began to feel stressed. My siblings are all very suc-
cessful and have prestigious jobs. My sister is an
attorney, my older brother is a doctor, and the other
is a philologist. During my first years of attending
school, I was successful as well. But then I started to
feel a lot of pressure and a lot of stress. I am sure
that my illness was to some extent induced by that
stress...»
Z.A. 34y. male, cannabis use since age 17
“Biological” or genetic models
Two patients put forward biological explanations for
why they were suffering from schizophrenia. Interest-
ingly though, biological explanations were only given as
part of a multi-factorial approach, when patients
described more than one contributing cause for their
illness.
«...On the other hand I am burdened by a family his-
tory with schizophrenia and that has practically to
do with it as well. My grandfather had this
disposition...»
Z.A. 34y. male, cannabis use since age 17
«...All three girls have problems. One of my sisters is
in psychiatric treatment as well. One person was
contagious, like spreading influenza... this person
was my mother»
N.A. 44y. female, cannabis use since age 20
Esoteric models
Magical explanatory models were adopted by two of our
patients. It has to be noted that both patients had an
immigrant background.
«...Having fever is being sick. Having cancer is being
sick. Vomiting is being sick. Having a headache is
being sick. What I have... I always have the feeling
that I do not have everything under control. But it is
not really an illness. It is power, and god gives this
power to me. I can hear my mother and my father
and also other dead people. I have been off to war
and I have killed people. People came to me. And
now I am scared of those people. I can see through
people. One glimpse is enough. This is a gift by
god...»
R.S. 51y. male, cannabis use since age 17
«...Back then I was very interested in occultism and
that is why I later got into trouble. I started to hear
voices and I was followed by demons...»
P.A. 27y. male, cannabis use since age 16
Patients’ view of a causal relationship between cannabis
use and schizophrenia
As seen above, one of the explanatory models was con-
nected to the use of substances, mainly focusing on the
role of hallucinogens and amphetamines. However, none
of the participants made a direct link between cannabis
consumption and the onset of psychotic symptoms in
their initial narrative statements. This was surprising to
us since a potential causal relationship between cannabis
use and schizophrenia is currently widely discussed in
the Swiss public. Upon further exploration concerning
the effects of their cannabis consumption, patients
expressed very differentiated views on that topic.
First, patients presupposed a clear temporal order
between consuming cannabis and the occurrence of psy-
chotic symptoms for assigning a causal role to their sub-
stance use:
«...I have tried to answer this question myself. I
really tried to put both things into connection after I
had a “mega"-psychosis. But I can assure you, it
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came not because of cannabis, this is not the origin
of it. I mean I believe that it can make some things
more apparent. Not must, but can. Really, it cannot
be the origin of it all, because I had these feelings,
long before I started with it...»
M.B.
In this context, cannabis use was clearly framed as a
consequence of psychotic symptoms rather than their
origin:
«...The scenario is this: You first go crazy and then
you start to smoke. It’s not the origin... it is rather
that you try to medicate yourself. ...»
Z.A.
Further, those questioned reasoned that possible nega-
tive effects of cannabis are related to the quality of the
cannabis preparation. Differentiating between “good”
and “bad” cannabis, they associated “good” cannabis
with positive effects, while the use of “bad” cannabis was
seen as resulting in negative experiences. In other
words, they feel on the safe side as long as they assure
using high quality preparations:
«...There is no causal relationship. Some slight influ-
ence: It depends on the quality of it. Sometimes it’s
worse, sometimes it’s better, but most often you feel
better...»
S.F.
In addition, patients stated that, in their view, adverse
reactions to cannabis are dose-related:
«...I am mentally unstable, not very stable. It can
really put me into it (psychosis) if I smoke every
day...once, or twice per week that is fine, at the max-
imum three times. You know, one glass of red wine
per day is fine too... as long as it does not become
three bottles. It all depends on the amount. For me
cannabis is a medical plant. You really can grow old
with it. Not like with hard drugs...»
P.O.
«...No. I would say if you consume it within a nor-
mal range it could have positive results. If you
overdo it then results will follow. If you take it
together with cocaine symptoms just intensify. I got
really anxious and then I started hearing voices...»
P.A.
Study participants moreover believed that the effects
of cannabis are varying between different individuals.
In these contexts, patients might use downward social
comparisons with sufferers experiencing more severe
psychotic symptoms than themselves by considering the
latter to be “more vulnerable” and thus feel somewhat
protected themselves:
«...Cannabis might have played a minor role. I just
believe that cannabis is different in every person.
You cannot really generalize it. ...»
K.C.
Finally, some study participants denied a causal con-
nection between cannabis use and their illness alto-
gether. This may be motivated by the fact that they
clearly distinguish between the causation of their illness
and an exacerbation of individual symptoms. As the fol-
lowing statements suggest:
«...It did not cause the voices...(but) it disturbs my
memory when I use it a lot...»
H.G.
«...No. I do not see a connection between my mental
problems and cannabis...»
N.A.
Effects of cannabis use, its advantages and disadvantages
Our study patients regarded the use of cannabis as an
important way of self-regulation and self-medication.
While most patients had a rather positive view of can-
nabis and used it (specifically) to reduce tension, to
attenuate symptoms of depression or (simply) for relaxa-
tion purposes, some raised concerns especially because
of its worsening psychotic symptoms and anxiety. Other
drawbacks of using cannabis included its causing of
increasing feelings of indifference and its acute aggravat-
ing of cognitive deficits.
Frequently it was a shared belief among all patients
that positive aspects prevailed over possible disadvan-
tages of cannabis use.
Most frequently, those questioned described that can-
nabis served them to reduce anxiety and tension
Patients’ statements may point to the fact they patients
perceive cannabis particularly helpful in reducing posi-
tive psychotic symptoms:
«...When I smoke it I am better, I am less scared and
I don’t have bad dreams anymore. I can “regenerate
my feelings” with it. Cannabis is an aid. It takes the
speed out of my thoughts, I can see my own
thoughts and I can arrange them properly...»
P.O.
«...I can calm down using it. It has something of a
ritual too, when I come home after work at night. It
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can reduce my anxiety. However, if it is bad stuff, it
can aggravate anxiety too. I just can lead a better life
with cannabis. It makes my problems bearable...»
S.F.
«...The voices (with my schizophrenia it is like this -
I only hear words, not sentences but words) go
away. It calms me down. It also reduces my chronic
pain and it loosens me up...»
N.A.
«... In the beginning I was fascinated by it, because I
could relax so easily. It helped me to put all other
things aside...»
P.A.
One patient even envisages a role of cannabis in sui-
cide prevention, assuming that stopping to use it may
exacerbate symptoms to such an extent that suicidal
behavior might ensue:
«...During psychosis it was different. I felt that some-
thing was going on and I thought that cannabis
might have different effects altogether. So I stopped
using it during this time. I had not used it for days
when I jumped...» (The patient had committed a sui-
cide attempt, by jumping out of the window)
M.B
Patients further identified benefits of cannabis in alle-
viating blunted affect, social withdrawal and lack of
motivation. Here, participants ascribed energizing and
mood-lifting effects to their cannabis use:
«...I see clear advantages. I am more of a “lonesome
wolf”. When my spirits are low, it is even worse. I
don’t want to see anybody. A joint can reverse this.
Before I go to work I need to smoke in order to
reduce my inner tension somewhat. It disturbs my
memory when I use it a lot.
Sometimes when I go shopping and I return, I have
forgotten something that I knew I wanted to get
before...»
H.G.
«...You cannot even imagine how tired I was. With it
I was more awake and I could think clearly. My
tiredness was attenuated and I felt more composed.
In the beginning it even improved my concentration
and my memory. Disadvantages: If it is of bad qual-
ity it makes me feel indifferent...»
Z.A.
«...I have more fantasy and I am more creative. In
school it really helped. I could write better essays. I
could read more and I was more active. With
cannabis I can also bear my crazy thoughts...discon-
nect. ...»
«...I use cannabis as an antidepressant medication...»
M.B.
Some participants expressed a differentiated view on
the effects of cannabis. In their view, effects of con-
sumption differ between phases of the illness and their
personal state, also implying negative outcomes if using
cannabis in the “wrong circumstances":
«...In 90% of the times I don’t have adverse effects.
In 10% of the times I get flashbacks. That is a price
I am willing to pay... Cannabis enhances my feelings
either way. If I have a bad day I will become more
depressed, on a good day I become more joyful...»
P.O.
«... When I first started using it and I was really ner-
vous and I smoked marijuana I was panicking... »
R.S.
Discussion
In this present exploratory study we examined disease
models expressed by cannabis using patients with schi-
zophrenia and clarified whether this patient group sus-
pected a causal link between cannabis use and their
illness.
We identified five major motives in the disease models
of schizophrenia patients with a co-occurring abuse of
cannabis: Mental illness was attributed towards upbring-
ing under difficult familial circumstances, to social pres-
sure, and to the use of legal and illegal substances.
Additionally, genetic and esoteric explanations were
given.
These motives do not fundamentally differ from expla-
natory models that have been elucidated in a study on
schizophrenia patients without a co-occurring substance
use disorder. Using a semi-structured interview, Anger-
meyer et al. (1988) identified recent psychosocial factors,
personality, family, biology, and esoteric reasons as
explanations put forward by patients suffering from
schizophrenia, schizo-affective disorders, and “affective
psychosis” [23].
Three patients favored a multi-modal explanation,
identifying more than one reason as causes for their
disorder. Again, this finding is in line with the results
of previous quantitative [23] and semi-quantitative stu-
dies [24]. Their causal explanations further reflect the
stress-vulnerability model underlying recent studies on
the etiology of psychosis in a framework of gene-envir-
onment interaction [25]. However, patients tended to
prefer psychological and social causes over genetic
explanations for their condition regardless of whether
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they thought they suffered from schizophrenia or from
other disturbances.
Interestingly, in this sample patients made a direct con-
nection between the use of hallucinogens and ampheta-
mines and the development of a mental illness at a later
time. With regard to cannabis such a relationship was
not made. One the contrary, apart from some adverse
effects, (e.g. induction of flashbacks and perturbance of
memory) patients had a rather positive view of cannabis
and stated to use it to reduce tension, to attenuate symp-
toms of depression, to blunt the disturbing effects of
acoustic hallucinations, or for relaxation purposes.
Furthermore, patients repeatedly described that they
had experienced mental health problems well before
they had started using cannabis, thus negating a causal
relationship between the use of cannabis and the onset
of schizophrenia all together.
Previous studies had found that reasons for cannabis
use among individuals with psychotic disorders mainly
comprised boredom, social motives, the wish to improve
sleep, anxiety and agitation, control of negative and
positive psychotic symptoms, increased energy levels,
and improved cognitive function [12,13].
A recent review, categorized reasons for cannabis use
in 4 main groups: enhancement of positive feelings,
relief of dysphoria, social reasons, and reasons related to
the illness and side effects of medication. It was found
that patients most commonly describe enhancement of
positive affect, relief from dysphoria and social enhance-
ment. Fewer patients reported reasons related to relief
of psychotic symptoms or relief of side effects of medi-
cation. Patients sometimes stated that cannabis nega-
tively affected positive symptoms [26].
Our results are in accordance with these findings.
The differentiation between “good” and “bad” cannabis
might relate to the findings of variable potency of can-
nabis extracts and its different ratios of Δ9-THC, CBD,
and other pharmacological active ingredients [27]. How-
ever, it has also been known for a long time that the
effects of cannabis are socially “constructed” and may
vary across different situations and expectations [28].
Our study has some important limitations. First, this is
an exploratory study aiming at an in-depth understand-
ing of patients’ views, thus using a small sample. Second,
all study patients were recruited from the same treat-
ment facility. Thus, it is unclear to what extent the pre-
sent findings can be generalized. The present results
should be verified in further studies involving more and
more diverse patients.
Conclusion
In summary, we found that patients with schizophrenia
had a rather positive view of cannabis. This perception
was reflected in their individual models of illness, which
negated a causal link between schizophrenia and canna-
bis. Thus, we suggest that clinicians consider these find-
ings in their work with patients suffering from such
co-occurring disorders. Frequently, cannabis use of
patients with schizophrenia has only been seen as a mis-
behavior leading to an untoward treatment outcome.
Therefore, it often resulted and still results in withhold-
ing treatment or excluding such patients from certain
treatment settings like day-care facilities or fulltime hos-
pitals (RS, personal communication). In view of the
beliefs surrounding cannabis use described above the
majority of this patient group may not understand such
an intervention. Rather patients may construe this thera-
peutic strategy as social rejection on the part of their
therapists, which has been shown to significantly contri-
bute to experiences of stigma and discrimination [29,30].
Stigma, then, has been found to act as an environmental
risk factor for the onset and course of schizophrenia [31].
Further, treatment approaches which do not take account
of patients’ subjective illness models are not likely to
enhance early help-seeking for psychosis and treatment
collaboration [32]. Moreover, given the missing scientific
evidence of deleterious effects of cannabis use on the
course of schizophrenia [3], we think that such confron-
tational approaches cause additional harm to this already
heavily burdened patient group. In conclusion patients’
causal attributions and individual recovery strategies
should be routinely explored in the context of the doc-
tor-patient-relationship.
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